Sofya N. Andreevskaya

Sofya N. Andreevskaya

Auto-generated profile, based on publicly available information

Sofya N. Andreevskaya

Central Tuberculosis Research Institute, Moscow, Russia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in Molecules
Verified
Journal Article
Open access
PDF file
AKAnastasia Khandazhinskaya
Anastasia Khandazhinskaya
LALiudmila Alexandrova
Liudmila Alexandrova
EMElena Matyugina
Elena Matyugina
PSPavel Solyev
Pavel Solyev
OEOlga Vladimir Efremenkova
Olga Vladimir Efremenkova
Katherine Seley-RadtkeKatherine Seley-Radtke
Katherine Seley-Radtke
A series of novel 5′-norcarbocyclic derivatives of 5-alkoxymethyl or 5-alkyltriazolyl-methyl uracil were synthesized and the activity of the compounds evaluated against both Gram-positive and Gram-negative bacteria. The growth of Mycobacterium smegmatis was completely inhibited by the most active compounds at a MIC99 of 67 μg/mL (mc2155) and a MIC99 of 6.7–67 μg/mL (VKPM Ac 1339). Several compounds also showed the ability to inhibit the growth of attenuated strains of Mycobacterium tuberculosis ATCC 25177 (MIC99 28–61 μg/mL) and Mycobacterium bovis ATCC 35737 (MIC99 50–60 μg/mL), as well as two virulent strains of M. tuberculosis; a laboratory strain H37Rv (MIC99 20–50 μg/mL) and a clinical strain with multiple drug resistance MS-115 (MIC99 20–50 μg/mL). Transmission electron microscopy (TEM) evaluation of M. tuberculosis H37Rv bacterial cells treated with one of the compounds demonstrated destruction of the bacterial cell wall, suggesting that the mechanism of action for these compounds may be related to their interactions with bacteria cell walls.

21 September 2019 in Molecules
Verified
Journal Article
Open access
PDF file
AKAnastasia Khandazhinskaya
Anastasia Khandazhinskaya
EMElena Matyugina
Elena Matyugina
PSPavel Solyev
Pavel Solyev
MWMaggie Wilkinson
Maggie Wilkinson
KBKaren W. Buckheit
Karen W. Buckheit
Katherine Seley-RadtkeKatherine Seley-Radtke
Katherine Seley-Radtke
Carbocyclic nucleosides have long played a role in antiviral, antiparasitic, and antibacterial therapies. Recent results from our laboratories from two structurally related scaffolds have shown promising activity against both Mycobacterium tuberculosis and several parasitic strains. As a result, a small structure activity relationship study was designed to further probe their activity and potential. Their synthesis and the results of the subsequent biological activity are reported herein.

15 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EAEvgeny Nikolaevich Antonov
Evgeny Nikolaevich Antonov
SASofya N. Andreevskaya
Sofya N. Andreevskaya
IBIrina V. Bocharova
Irina V. Bocharova
SBSergei E. Bogorodsky
Sergei E. Bogorodsky
LKLarisa Krotova
Larisa Krotova
Vladimir K. PopovVladimir K. Popov
Vladimir K. Popov
Levofloxacin (LFX) is a highly effective anti-tuberculosis drug with a pronounced bactericidal activity against Mycobacterium tuberculosis (Mtb). In this work, an “organic solvent-free” approach has been used for the development of polylactic-co-glycolic acid (PLGA) microparticles and scaffolds containing LFX at a therapeutically significant concentration, providing for its sustained release. To achieve the target, both nonpolar supercritical carbon dioxide and polar supercritical trifluoromethane have been used. By changing the composition, surface morphology, size, and internal structure of the polymer carriers, one can control the kinetics of the LFX release into phosphate buffered saline solutions and physiological media, providing for its acceptable burst and desirable concentration in the prolonged phase. The biocompatibility and bactericidal efficacy of PLGA/LFX carriers assessed both in vitro (against Mtb phagocytosed by macrophages) and in vivo (against inbred BALB/c mice aerogenically infected with Mtb) demonstrated their anti-tuberculosis activity comparable with that of the standard daily intragastric levofloxacin administration. These results make it possible to consider the developed compositions as a promising candidate for anti-tuberculosis control release formulations providing for the further evaluation of their activity against Mtb and their metabolism in vivo over long periods of tuberculosis infection.

4 July 2023 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
SAS. N. Andreevskaya
S. N. Andreevskaya
ELE. E. Larionova
E. E. Larionova
EKE. A. Kiseleva
E. A. Kiseleva
LCL. N. Chernousova
L. N. Chernousova
SKSvetlana Kayukova
Svetlana Kayukova
The objective: to evaluate changes in detection frequency of Mycobacterium tuberculosis of the main phylogenetic lines with various genetic determinants of resistance to rifampicin, isoniazid and fluoroquinolones in 1998–2003 and 2016–2021.Subjects and Methods. 965 mycobacterial cultures were studied, those cultures were isolated from pulmonary tuberculosis patients in 1998–2003 and 2016–2021. The spoligotypes of isolated Mycobacterium tuberculosis cultures and presence of gene mutations associated with resistance to isoniazid, rifampicin, and fluoroquinolones were determined.Results. In 2016–2021 versus 1998–2003, the incidence of Beijing subline increased from 50,72% to 64,60%. Within Euro-American line, the detection frequency of subline LAM9 decreased (from 40,00% to 14,81%), while the detection frequency of sublineT1 increased (from 27,11% to 41,36%). Mycobacterium tuberculosis with MDR genotype rpoB531_Ser->Leu + katG315_Ser-> Thr [1] was selected. Mycobacterium tuberculosis with genotypic resistance to fluoroquinolones was detected only in cultures of 2016–2021, and Mycobacterium tuberculosis with preXDR genotype was significantly more common in Beijing subline compared to Euro-American line (21,67% vs. 3,73%, p <0,05).

1 January 2016 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
SAS.N. Andreevskaya
S.N. Andreevskaya
ELE.E. Larionova
E.E. Larionova
TSTatiana Gennadievna Smirnova
Tatiana Gennadievna Smirnova
IAI.Yu. Andrievskaya
I.Yu. Andrievskaya
EKE.A. Kiseleva
E.A. Kiseleva
LCL.N. Chernousova
L.N. Chernousova

21 December 2019 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
AEAtadzhan E. Ergeshov
Atadzhan E. Ergeshov
LCLarisa N. Chernousova
Larisa N. Chernousova
SASofya N. Andreevskaya
Sofya N. Andreevskaya
АНАндреевская Софья Николаевна
Андреевская Софья Николаевна
Widespread drug-resistant tuberculosis is a global challenge that has a potential to have a negative impact on the global TB situation. Rapid TB diagnosis and early initiation of effective treatment based on the individualized chemotherapy regimens underpin efforts in prevention of further spread of tuberculosis. Microbiological methods of TB diagnosis that provide evidence of the TB process etiology and identify drug susceptibility of the pathogen play a very important role. The review covers the current and emerging methods of the microbiological TB diagnosis including conventional microbiological (microscopy of diagnostic material, cultural studies on solid media and culture fluids) and modern molecular genetic tests (DNA strips, biological microchips, multiplex PCR, GeneXpert and diagnostic systems of the new generation and point-of-care tests) and demonstrates the role of the described methods in the diagnostic TB laboratory algorithm. The example of the Microbiology Department of the Central TB Research Institute illustrates the effectiveness of modern developments in the diagnosis of drug-resistant tuberculosis and their impact on improving treatment success in the clinical departments of the CTRI. The review presents further prospects of drug-resistant TB diagnosis in relation to the new technologies such as Next Generation Sequencing. The conclusion summarizes information on the current state of microbiological diagnosis of drug-resistant tuberculosis and emphasizes the importance of developing and introducing new technologies into the diagnostic process.